Assisted Living Locators, a leading nationwide senior placement and referral service, is going purple for the fourth annual year this June in support of Alzheimer's & Brain Awareness Month. The ...

Emily Bodnar, an analyst at H.C. Wainwright, raised her price target for Purple Biotech Ltd. (NASDAQ:PPBT) from $33 to $34 ...

AI will deliver transformative therapies at an exponential scale, addressing the complexities of biology that traditional ...

Nikhil Srivastava joins other Indian executives at KKR, Blackstone and Warburg Pincus who have taken on global leadership ...

Lindsay Hubbard opened up about how Turner Kufe feels about Carl Radke. Read on to see what she said about their dynamic.

Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented ...

Pre-clinical research collaboration with Icahn School of Medicine at Mount Sinai for CAPTN-3 tri-specific antibody platform Purple Biotech entered into a Research Collaboration Agreement with the ...

His extensive experience in the U.S. and European biotech and pharma markets, coupled with his passion for guiding companies towards financial success, make him a great match for Purple Biotech as ...

REHOVOT, Israel - Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company with a market capitalization of $6.07 million, today announced the appointment of Shai Lankry as ...

including leading a U.S. IPO and M&A transaction “I’m excited to join Purple Biotech at such a pivotal time,” said Mr. Lankry. “The Company’s innovative science and commitment to ...

REHOVOT, Israel - Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company with a market capitalization of $6.07 million, today announced the appointment of Shai Lankry ...

REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...